» Articles » PMID: 14990788

Expression and Activation of the Farnesoid X Receptor in the Vasculature

Overview
Specialty Science
Date 2004 Mar 3
PMID 14990788
Citations 79
Authors
Affiliations
Soon will be listed here.
Abstract

The farnesoid X receptor/bile acid receptor (FXR) is a recently discovered member of the nuclear hormone superfamily. FXR ligands have been proposed as targets in cardiovascular disease, regulating cholesterol metabolism and bile acid transport and metabolism in the liver and gastrointestinal tract. When we used a human cardiovascular tissue array, we found that FXR is expressed in a variety of normal and pathological human tissue. Particularly high levels of FXR were found in the vasculature and in a number of different metastatic cancers, as well as the previously identified target tissues of the liver, small intestine, and kidney. In vitro, FXR is present in rat and human vascular smooth muscle cells. When treated with a range of FXR ligands, vascular smooth muscle cells undergo apoptosis in a manner that correlates with the ligands' ability to activate FXR. Furthermore, FXR activators induce mRNA for the FXR target genes, phospholipid transfer protein, and the small heterodimer partner. FXR therefore is a functional protein in the vasculature that may provide a direct target for the treatment of proliferative and dyslipidaemic diseases.

Citing Articles

Bile acids and incretins as modulators of obesity-associated atherosclerosis.

Kirsch A, Gindlhuber J, Zabini D, Osto E Front Cardiovasc Med. 2025; 11():1510148.

PMID: 39834741 PMC: 11743266. DOI: 10.3389/fcvm.2024.1510148.


The Gut-Heart Axis: Effects of Intestinal Microbiome Modulation on Cardiovascular Disease-Ready for Therapeutic Interventions?.

Sagmeister A, Matter C, Stahli B, Scharl M Int J Mol Sci. 2025; 25(24.

PMID: 39769292 PMC: 11676197. DOI: 10.3390/ijms252413529.


How bile acids and the microbiota interact to shape host immunity.

Lee M, Nuccio S, Mohanty I, Hagey L, Dorrestein P, Chu H Nat Rev Immunol. 2024; 24(11):798-809.

PMID: 39009868 DOI: 10.1038/s41577-024-01057-x.


Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development.

Li T, Chiang J Pharmacol Rev. 2024; 76(6):1221-1253.

PMID: 38977324 PMC: 11549937. DOI: 10.1124/pharmrev.124.000978.


Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets.

Fleishman J, Kumar S Signal Transduct Target Ther. 2024; 9(1):97.

PMID: 38664391 PMC: 11045871. DOI: 10.1038/s41392-024-01811-6.


References
1.
Howard W, Pospisil J, Njolito E, Noonan D . Catabolites of cholesterol synthesis pathways and forskolin as activators of the farnesoid X-activated nuclear receptor. Toxicol Appl Pharmacol. 2000; 163(2):195-202. DOI: 10.1006/taap.1999.8869. View

2.
Broughton 2nd G . Chenodeoxycholate: the bile acid. The drug. a review. Am J Med Sci. 1994; 307(1):54-63. DOI: 10.1097/00000441-199401000-00011. View

3.
Niesor E, Flach J, Perez A, Bentzen C . The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001; 7(4):231-59. DOI: 10.2174/1381612013398185. View

4.
Alberts D, Hallum 3rd A, Garcia D, Salmon S, Santabarbara P, Niesor E . Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. Clin Cancer Res. 2001; 7(5):1246-50. View

5.
Willson T, Jones S, Moore J, Kliewer S . Chemical genomics: functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism. Med Res Rev. 2001; 21(6):513-22. DOI: 10.1002/med.1023. View